When women ask about hormones, they are usually handed an estrogen story. Yet low testosterone in women is the decline nobody measures, even though testosterone is the hormone most responsible for drive, muscle and resilience in women. Fatigue that sleep does not fix, a libido that quietly went offline, strength you cannot rebuild no matter how consistently you train and a mood that flattened are the recognized symptoms. They deserve measurement rather than dismissal. We see this pattern constantly in women between 35 and 55 whose other labs are spotless and whose concerns were filed under stress.

Women produce testosterone in the ovaries and the adrenal glands and circulating levels begin declining gradually through the thirties and forties, with a further drop around surgical menopause. The symptoms of that decline overlap with perimenopause, thyroid dysfunction, sleep deprivation and life itself, which is precisely why a careful evaluation matters and why neither dismissing the complaint nor prescribing on vibes is acceptable.

Key Takeaways
  • Low testosterone in women is rarely measured, even though it drives libido, mood, muscle and cognition.
  • The Global Consensus Position Statement recognizes only one established indication: hypoactive sexual desire disorder in postmenopausal women.
  • Standard panels, wide reference ranges, SHBG shifts and poor assay accuracy at female concentrations all contribute to missed diagnoses.
  • Unmonitored pellets and high-dose creams can cause irreversible supraphysiologic side effects, the opposite failure from dismissal.
  • A proper workup pairs LC-MS testosterone and SHBG with thyroid, iron and cardiometabolic markers, not testosterone in isolation.
  • The Cardiometabolic Optimization Membership includes quarterly Biomarker Audits and bills hormone prescriptions at pharmacy cost with zero markup.

What low testosterone looks like in women

The symptom picture is consistent across the clinical literature:

  • Sexual health. Reduced desire, weaker arousal and diminished orgasm intensity. This cluster has the strongest evidence base and is the primary indication studied in trials.
  • Energy and mood. Persistent fatigue, reduced motivation, flat affect and a subjective sense of losing one's edge.
  • Muscle and strength. Difficulty building or maintaining lean mass despite resistance training, alongside increased central fat.
  • Cognition. Brain fog and reduced concentration, often coexisting with perimenopausal changes.
  • Bone. Longstanding deficiency contributes to reduced bone density, though this is rarely the presenting complaint.

The Global Consensus Position Statement on testosterone therapy for women, published by a multidisciplinary panel of menopause and endocrine societies, reviewed the evidence and concluded that the only established indication for treatment in women is hypoactive sexual desire disorder, where postmenopausal women treated with physiologic-dose testosterone showed meaningful improvement [1]. That position matters because it separates responsible therapy from the internet's version of it. It also does not mean the other symptoms should be ignored. It means they should be evaluated in full context, because the cause may be thyroid, iron, sleep, perimenopause or several at once.

Why the diagnosis gets missed, in both directions

Standard panels rarely include testosterone for women and reference ranges are wide, so a symptomatic woman frequently sits inside the laboratory's normal band while feeling distinctly abnormal.

Clinical note

SHBG rises with oral estrogen therapy and with age relative to body composition, lowering the free fraction of testosterone. And assay accuracy at female concentrations is poor on many standard platforms, so a number can be wrong before it is interpreted.

The opposite failure is the boutique clinic that measures once, finds a lowish value and starts pellets or high-dose cream with no protocol for monitoring.

Clinical note

Pellet therapy in particular has a structural problem we have written about before: the implanted dose cannot be adjusted after insertion, so side effects become removal procedures rather than dose changes. Supraphysiologic dosing in women produces acne, hair loss, voice deepening and clitoromegaly, some of which can be irreversible.

We critique that model, not any named company, but the model deserves it.

What responsible evaluation and treatment look like

A proper workup measures total testosterone with a liquid chromatography-tandem mass spectrometry assay where available, SHBG and an albumin-derived free testosterone calculation, alongside the rest of the endocrine picture:

Core Lab Panel for Women

What each test reveals

LabWhat it tells your physician
Total testosterone, LC-MS methodThe most accurate measure at female concentrations
SHBGExplains how much hormone is bioavailable versus bound
Free testosterone, calculatedThe fraction doing the actual work
Estradiol and progesteroneSituates the complaint within the ovarian cycle or perimenopause
TSH and free T4Rules thyroid in or out, since symptoms overlap almost completely
Ferritin and CBCIron deficiency masquerades as fatigue and hair changes
HbA1c, lipids, ApoB, hs-CRPPlaces everything inside the cardiometabolic picture

That final row is our differentiator and it is not incidental. Hormonal symptoms in women rarely arrive alone. Insulin resistance worsens androgen profiles, thyroid dysfunction mutes everything and cardiovascular risk accumulates silently through the same decades. Our Biomarker Audit every 90 days reads the full panel together, so a woman presenting with fatigue and low libido gets an answer that spans endocrine, metabolic and cardiovascular health as one system.

When treatment is indicated, the evidence supports physiologic-dose testosterone, typically delivered as a low-dose cream or compounded preparation titrated carefully, with monitoring of levels and symptoms. Compounded bioidentical hormone therapy is legitimate here, including BIEST for estrogen and progesterone needs in appropriate patients. What is never acceptable is supraphysiologic dosing, unmonitored pellets or androgens marketed as optimization. Treatment targets symptom relief at levels that stay inside the female physiologic range.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

The objection about long-term safety, answered honestly

The most common reason women hesitate is the memory of the Women's Health Initiative era, when hormone therapy was widely reported as dangerous. The modern reading of that evidence is far more nuanced. WHI's findings were driven largely by estrogen-plus-progestin in older women years past menopause and subsequent analyses and trials, including the 20-year follow-up published in JAMA and the TRAVERSE cardiovascular data in men, have substantially revised the risk picture for appropriately selected, appropriately timed therapy [2]. Testosterone therapy at female physiologic doses has been studied mainly over 52-week horizons, where it showed no excess adverse events, while long-term safety surveillance remains thinner than for estrogen therapy. We say that plainly: the desire indication has solid 52-week safety data and an honest clinician will tell you the decade-long data in women is limited.

That honesty is why monitoring cadence matters more in women than in men. Our quarterly Biomarker Audit exists partly for this reason. Levels, hematologic markers, lipids and metabolic values are re-read every 90 days and dose follows the data rather than the marketing calendar.

The economics, because you should always see the math

The Cardiometabolic Optimization Membership is one flat $299 per month with no tiers, beginning with a $598 first charge covering the initial two-month commitment, then $299 monthly, cancel anytime after. The comprehensive Biomarker Audit every 90 days is included in the fee. Medication and hormone prescriptions are billed separately by the pharmacy at pharmacy cost with zero markup from us.

What the membership includes
$299/mo
Cardiometabolic Optimization Membership, flat fee, no tiers
$598
First charge covering the initial two-month commitment
90 days
Biomarker Audit monitoring cadence, included in the fee
52-week
Duration most testosterone safety data in women currently covers

One flat fee for the doctor. Zero markup on the medicine.

Because our revenue never scales with your dose, titration aims at the least hormone that delivers the most symptom relief and declining to treat is an answer we give freely when the evidence does not support it. Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols.

Who this article is for

If you are a woman whose complaint is drive, energy, strength or mood and you have been told your labs are normal without anyone actually measuring the hormone that governs those functions, the next step is a proper panel rather than a supplement aisle. If you are already on hormone therapy that nobody is monitoring, the next step is the same: measure, interpret and adjust against data. Both conversations start the same way, with a clinician who reads the full hormone picture alongside the metabolic one, which is the model this practice was built on.

FAQ

What are the symptoms of low testosterone in women?

Reduced libido, persistent fatigue, difficulty building or keeping muscle, flat mood, brain fog and reduced orgasm intensity. Symptoms overlap with thyroid and perimenopausal changes, so evaluation should include those too.

Is testosterone therapy approved for women?

No testosterone product is FDA approved for women in the United States. Clinicians prescribe physiologic-dose therapy off-label and the Global Consensus Position Statement supports it for postmenopausal hypoactive sexual desire disorder.

What dose of testosterone do women take?

Roughly one tenth of typical male dosing, titrated to keep levels within the female physiologic range. Supraphysiologic dosing causes irreversible androgenic effects and is never appropriate.

Are testosterone pellets safe for women?

They carry a specific structural risk: the implanted dose cannot be adjusted after insertion, so excess hormone requires removal rather than a dose change. We prefer titratable delivery when therapy is indicated.

Can low testosterone in women be treated with bioidentical hormones?

Yes. Physiologic-dose compounded bioidentical testosterone, often alongside estrogen and progesterone support such as BIEST where indicated, is the standard approach, monitored with periodic levels.

How is treatment monitored?

Levels, symptoms and metabolic markers are re-checked on a scheduled cadence. Our Biomarker Audit every 90 days is included in the membership and provides that monitoring.

What does GoodLife Health's membership cost?

One flat $299 per month with no tiers, beginning with a $598 first charge for the initial two-month commitment. Medication is separate, billed by the pharmacy at pharmacy cost with zero markup.

Is low testosterone in women the same as perimenopause?

No, but they overlap. Perimenopause involves fluctuating estrogen and progesterone and testosterone declines gradually across the same years. A full panel distinguishes what is actually driving your symptoms.

One last thing

Women have spent decades being offered either dismissal or overcorrection and both come from the same failure: nobody wanted to measure carefully and titrate patiently. The middle path is slower, more honest and better. Measure first, treat only what the evidence supports and adjust against data every quarter.

Related guides

References

  1. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. 2015. doi.org/10.1210/jc.2015-2236
  2. Testosterone in Women — The Clinical Significance (Lancet Diabetes & Endocrinology). 2015. doi.org/10.1016/S2213-8587(15)00284-300284-3)